Source comparison
Best KPV Dosage Antimicrobial 2026: Pathogen-Specific Protocols Comparison
Staphylococcus aureus (MSSA) 250–500 1,000–1,500 Once daily 12–18 Subcutaneous 500mcg once daily provides reliable coverage; oral requires split dosing Staphylococcus aureus (MRSA) 500–750 1,500–2,500 Twice daily 20–30 Resistant strains demand higher trough le
This comparison does not assign a generated winner or score.
- Staphylococcus aureus (MSSA)
- 250–500
- 1,000–1,500
- Once daily
- 12–18
- Subcutaneous 500mcg once daily provides reliable coverage; oral requires split dosing
- Staphylococcus aureus (MRSA)
- 500–750
- 1,500–2,500
- Twice daily
- 20–30
- Resistant strains demand higher trough levels; single daily dosing insufficient for either route
- Escherichia coli
- 1,000–2,000
- 10–15
- Gram-negative strains respond at lower concentrations; 500mcg subcutaneous is optimal
- Pseudomonas aeruginosa
- 500–1,000
- 2,000–3,000
- 25–40
- Biofilm-producing strains require sustained high-level exposure; oral route struggles to maintain MIC
- Candida albicans (fungal)
- 750–1,000
- 2,500–4,000
- 30–50
- KPV shows moderate antifungal activity but requires near-peak dosing for efficacy
- The comparison makes the route-pathogen interaction clear: for resistant strains or biofilm producers, subcutaneous administration at the high end of the range (750–1,000mcg split into twice-daily dosing) outperforms oral protocols even at 3–4× total daily dose. Plasma level consistency matters more than peak level for pathogens with high MIC thresholds.